. 2014 Aug 5;15(3):365–379. doi: 10.1007/s11864-014-0294-4

Table 2.

Clinical trials of mTOR inhibitors in Pancreatic NET tumors

	Agent	No. patients	Tumor response rate (%)	Median TTP or PFS	Reference
Phase II studies
	Everolimus^a	30	27	50 wk	Yao et al. 2008 [37]
RADIANT-1	Everolimus	115	9	9.7 mo	Yao et al. 2010 [31]
	Everolimus + octreotide	45	4	16.7 mo	Yao et al. 2010 [31]
	Temsirolimus^a	15	7	10.6 mo	Duran et al. 2006 [41]
Phase III studies
RADIANT-3	Everolimus vs.	207	5	11 mo	Yao et al. 2011[8••]
RADIANT-3	Placebo	203	2	4.6 mo	Yao et al. 2011[8••]
CALGB 80701	Everolimus + octreotide vs.	Ongoing
CALGB 80701	Everolimus + bevacizumab + octreotide	Ongoing

PFS progression-free survival, TTP time to progression

^a Data from the subset of patients with pancreatic NET in this phase II study of unselected patients with NET are presented